Litigation Details for Pacira Pharmaceuticals, Inc. v. Research Development Foundation (D. Nev. 2021)
✉ Email this page to a colleague
Pacira Pharmaceuticals, Inc. v. Research Development Foundation (D. Nev. 2021)
| Docket | ⤷ Try a Trial | Date Filed | 2021-12-23 |
| Court | District Court, D. Nevada | Date Terminated | |
| Cause | 28:2201 Declaratory Judgment | Assigned To | Richard Franklin Boulware II |
| Jury Demand | Both | Referred To | Daniel J. Albregts |
| Parties | RESEARCH DEVELOPMENT FOUNDATION | ||
| Patents | 9,585,838 | ||
| Attorneys | Gregg LoCascio | ||
| Firms | Kirkland and Ellis LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Pacira Pharmaceuticals, Inc. v. Research Development Foundation
The small molecule drug covered by the patent cited in this case is ⤷ Try a Trial .
Details for Pacira Pharmaceuticals, Inc. v. Research Development Foundation (D. Nev. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-12-23 | 1 | remaining patent covered by the Agreements is United States 26 Patent No. 9,585,838 (the “’838 Patent”), entitled…certain patents or patent applications for only as 26 long as those particular patents or patent applications… in an Assigned Patent (or a patent application if the 4 resulting Letters Patents would constitute…Amendment. The ’495 Patent does not claim priority to any 15 earlier patent or patent application, nor …related to any patents or patent applications covered by 16 the Agreements. The ’495 patent was issued | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
